Acest proiect trateaza Antibiotice Iasi. Mai jos poate fi vizualizat un extras din document (aprox. 2 pagini).
Arhiva contine 1 fisier doc de 19 pagini .
Iti recomandam sa te uiti bine pe extras si pe imaginile oferite iar daca este ceea ce-ti trebuie pentru documentarea ta, il poti descarca. Ai nevoie de doar 4 puncte.
Extras din document
The purpose of this paper is to present an overall analysis of the strategic management of the company Antibiotice SA in terms of internationalization of the company. Our aim is to analyze the mission, vision and values of the company, how the strategy is implemented, if there are any limitations in managing the strategies and in the same time to see how the company decides and evaluates these strategies across the borders.
The research for this paper was conducted through a detailed information gathering concerning the company’s activity. We also used several documents and presentation brochures of the company, in order to read only recent information.
The pharmaceutical industry is the world’s largest industry due to worldwide revenues of approximately US$2.8 trillion. Pharmaceutical industry has faced major changes in the recent years that place new demands on payers, providers and manufacturers. Customers now demand the same choice and convenience from pharmaceutical industry that they find in other segment.
Antibiotice SA is an independent health care pharmaceutical organization. The industry is mainly involved in manufacturing generic drugs. The company is the supplier of injectable cephalosporin and anti-infective. Antibiotice develops new and competitive pharmaceutical products within its research department and formulation, optimizing the formula of traditional products (ointment bases and modern excipients) and diversifying the product portfolio of the company. The organization develops third and fourth generation of oral and injectable cephalosporin, combinations of penicillin with beta-lactam inhibitors and quinolones. The company formulations are available in various dosage forms: powders for injectable solutions and suspensions, capsules tablets, ointments, gels, creams and active ingredient Nystatin. Antibiotice is headquartered in Iaşi, Romania.
1. Description of the company
With 55 years of tradition in the field of generic drug manufacturing and a complex portfolio comprising over 130 medicines covering 10 therapeutic classes, Antibiotice is the only producer of injectable cephalosporin and the main producer of anti-infective in Romania.
In addition, Antibiotice S.A is leader on the domestic market of the solutions and suspensions for injection filled into vials in terms of physical units.
The quality of the company products is attested by the Good Manufacturing Practice (GMP) Certificate, the Certificate of Suitability to the European Pharmacopoeia and acceptance by the Food and Drug Administration (FDA) for the US and Canadian markets.
At present, the company has 8 production lines, all GMP certified, for the manufacturing of 5 dosage forms (powders for injectable solutions and suspensions, capsules tablets, ointments, gels, creams and suppositories) and of the active ingredient Nystatin.
1955-1959 – In December 1955 came into being the first Romanian pharmaceutical company. Shortly after, Antibiotice became the first East European company producing on large scale Alexander Fleming’s famous discovery: penicillin. Four years later, the streptomycin production facility started operating and the manufacturing of ointments, creams and suppositories was initiated.
1977-1989 – In the 80’s Antibiotice already exported 50% of its production. Thus, the active ingredients manufactured in Iaşi became an essential element of a wide range of medicines produced both in the country and worldwide. A number of 44 letters patents in the pharmaceutical field were registered and 600 technical innovations were implemented in production in the same period.
1997-2000 – Constantly concerned about the quality of its products, in 1997 the company started to implement an effective quality assurance system requiring the strict control of the manufacturing processes. Thus, in 1999, Antibiotice became the first Romanian producer to obtain the Good Manufacturing Practice (GMP) Certificate for the facility of powders for injectable medicines. The ascendant financial evolution resulted in an important achievement: the company was listed to the Stock Exchange Bucharest.
2005 - Upon celebrating 50 years of activity, Antibiotice launched a new corporate brand identity. Starting with December, the company had a new logo and a new slogan which reflect the massive transformations undergone by the company in terms of organizational structure, technology, and culture.
2006 - LLOYD’S REGISTER QUALITY ASSURANCE granted Antibiotice the ISO 9001:2000 certificate for the Quality Management System in the field of pharmaceutical product manufacturing.
With 58th years of tradition in the pharmaceutical industry, Antibiotice is the main anti-infective drug manufacturer (the only injectable cephalosporin manufacturer). The company is a leader in the manufacturing of sterile powders for solutions and injectable suspensions and it is also the major producer of ointments, creams, gels and suppositories.
The last few years, in accordance with the ascendant trend of the Romanian pharmaceutical industry, the company has developed the cardiovascular, dermatology and CNS range, enhancing its complex portfolio which comprises over 130 drugs covering 10 therapeutic classes.
Fisiere in arhiva (1):
- Antibiotice Iasi.doc